Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
Executive Summary: What This Report Finds
This report reviews clinical evidence through mid-2026, including a 2025 open-label randomized trial, a 2026 real-world cohort study of 94 patients, and the National Psoriasis Foundation’s 2026 primer in JAMA Dermatology. Semaglutide shows meaningful potential to improve psoriasis, especially in patients who also have excess weight or type 2 diabetes, yet it remains an off-label option that requires careful medical oversight.1
Our practice offers medically supervised peptide therapy, including semaglutide and other GLP-1 receptor agonists, for patients who want an integrated approach to metabolic and inflammatory health under the direct care of our board-certified plastic surgeon.
Schedule a consultation to see whether a supervised semaglutide protocol fits your health profile.
Evidence Review Approach for This Report
This report draws on peer-reviewed clinical studies identified through systematic searches of PubMed and Scopus, the 2026 systematic review by Marani et al. in the Journal of Clinical Medicine analyzing 26 studies, the National Psoriasis Foundation Medical Board primer in JAMA Dermatology, and real-world pharmacovigilance data. Evidence quality ranges from randomized trials to case reports, and findings are weighed accordingly throughout this report.
This structured approach separates the analysis from anecdotal social media content and from older clinical literature that predates the pivotal 2025–2026 evidence base.
How Semaglutide Connects Metabolic Health and Psoriasis
Psoriasis is a chronic immune-mediated inflammatory disease driven by cytokines including IL-17, IL-23, and TNF-α. Obesity and type 2 diabetes amplify systemic inflammation, because adipose tissue acts as an immunologically active organ that produces pro-inflammatory cytokines. This heightened inflammatory state worsens psoriatic disease activity and can reduce the effectiveness of biologic therapies.
GLP-1 receptors have been identified in psoriatic plaques but not in unaffected skin, which suggests a potential direct role in lesional immune responses. Semaglutide operates through a dual mechanism. It reduces inflammatory markers such as IL-6 and C-reactive protein (CRP), and it produces weight loss that lessens the overall inflammatory burden.
GLP-1 receptor activation suppresses NF-κB, JAK2/STAT3, and SOCS3 signaling in keratinocytes through AMPK activation, which reduces secretion of pro-inflammatory cytokines such as TNF-α and IL-6. In addition, GLP-1 receptor agonists modulate the IL-23/Th17/IL-17 axis, a central inflammatory pathway in psoriasis, by reducing dermal γδ T-cell numbers and IL-17 expression in psoriatic skin.
Key Finding #1: Semaglutide Improves Psoriasis Severity
The strongest evidence comes from four sources published in 2025–2026.
First, the 2025 open-label randomized trial by Petković-Dabić et al. enrolled 31 patients with psoriasis, obesity, and type 2 diabetes. Median PASI improved from 21 to 10 and DLQI from 14 to 4.1 Among the 15 semaglutide-treated patients, 13 achieved PASI90 and one achieved PASI100 after 12 weeks.1
Building on this, the 2026 retrospective cohort study by Bar et al. at Sheba Medical Center found that 44.4% of GLP-1-treated patients achieved clear or almost-clear skin (IGA 0/1) at 48 weeks versus 12.1% of controls (P < .001).1 Among patients receiving both a GLP-1 and a biologic, 85.0% achieved IGA 0/1 compared with 52.5% on biologics alone (P = .029).1 Semaglutide-specific analysis showed an adjusted odds ratio of 3.12 for achieving IGA 0/1.1
In parallel, the 2026 systematic review by Marani et al. analyzed 26 studies and reported substantial PASI reductions across semaglutide studies.1 The National Psoriasis Foundation’s 2026 JAMA Dermatology primer similarly found GLP-1 receptor agonists associated with 40–80% PASI reductions in patients with psoriasis.1
Key findings from the 2025–2026 evidence base include the following:
- Semaglutide produced large PASI reductions across multiple 2025–2026 studies.1
- In a 2025 randomized trial, 13 of 15 patients achieved PASI90 after 12 weeks of semaglutide.1
- A 2026 cohort study found GLP-1 therapy produced clear or almost-clear skin in 44.4% of patients versus 12.1% of untreated controls.1
- Semaglutide lowered inflammatory markers including IL-6 and C-reactive protein in psoriasis patients.1
- Weight loss accounted for approximately 38% of the skin improvement, which indicates additional direct anti-inflammatory effects.1
| Study (Year) | Design | Key Psoriasis Finding |
|---|---|---|
| Petković-Dabić et al. (2025) | Open-label RCT, 31 patients | Median PASI 21→10; 13/15 achieved PASI90 |
| Bar et al. (2026) | Retrospective cohort, 94 patients | 44.4% achieved IGA 0/1 vs. 12.1% controls |
| Nicolau et al. (2026) | Prospective cohort, 43 patients | Mean PASI 10.6→5.5 (48% reduction)1 |
| Marani et al. (2026) | Systematic review, 26 studies | Consistent PASI reductions across studies1 |
How Semaglutide Compares with Other GLP-1s and Biologics
Biologics, including IL-17 and IL-23 inhibitors, directly target specific immune pathways driving psoriasis and remain the gold standard for moderate-to-severe disease. Semaglutide works differently. It reduces metabolic inflammation and produces weight loss, which indirectly improves psoriasis and may enhance biologic efficacy. The 2026 Bar et al. cohort study found that adding a GLP-1 to biologic therapy increased clear or almost-clear response rates from 52.5% to 85.0%.1
Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist with similar anti-inflammatory potential and may produce somewhat larger reductions in inflammatory markers due to greater weight loss. However, psoriasis-specific evidence is more limited for tirzepatide than for semaglutide, which has been studied in randomized trials and large cohort studies. Among GLP-1 receptor agonists, semaglutide and liraglutide show the most consistent evidence of benefit for psoriasis.
Key Finding #2: Safety Profile and Psoriasis Risk
Current evidence suggests that semaglutide rarely triggers psoriasis, although a small safety signal exists in large observational data.
A 2026 target trial emulation study using the TriNetX US Collaborative Network, which matched 169,630 GLP-1 users with 169,630 DPP-4 inhibitor users, found GLP-1 use was associated with a 19% relatively higher risk of new-onset psoriasis compared with DPP-4 inhibitors (HR 1.19; 95% CI 1.11–1.28). The absolute risk increase was small at 0.05% over 2 years, or roughly one additional case per 1,200 patients treated. This signal comes from observational data and does not prove causation.
The 2026 Marani systematic review identified no cases of semaglutide-triggered psoriasis flares, although rare paradoxical reactions have been reported with other GLP-1 drugs, particularly exenatide. Common skin-related side effects of GLP-1 drugs include injection site reactions, temporary hair loss (telogen effluvium) from rapid weight loss, and facial volume loss sometimes called “Ozempic face.” Any skin changes during semaglutide therapy should be discussed promptly with a healthcare provider.
Key Finding #3: Patients Most Likely to Benefit
Semaglutide appears most helpful for psoriasis patients who also have obesity (BMI ≥ 30) or overweight with comorbidities, type 2 diabetes or prediabetes, or metabolic syndrome features. The National Psoriasis Foundation recommends GLP-1 receptor agonists as adjunctive therapy for these patients, rather than as a standalone psoriasis treatment.
For a normal-weight patient with mild psoriasis and no metabolic issues, semaglutide usually offers limited value. Evidence-based psoriasis therapies such as topicals, phototherapy, or biologics should remain the primary treatment, with GLP-1 therapy considered as a complement when metabolic disease is present.
Patient Experiences from Online Communities
Patient forums and social media communities describe a wide range of experiences with semaglutide and psoriasis. Some individuals report noticeably clearer skin within weeks to months of starting the medication.1 Others describe no change in their psoriasis despite meaningful weight loss, and a small number report flare-ups during the early weeks of treatment.1
Anecdotes do not replace clinical trials, and individual results vary based on genetics, psoriasis type, metabolic status, concurrent treatments, and dosing protocol.
Checklist for Discussing Semaglutide with Your Doctor
- Ask whether semaglutide fits your psoriasis severity, BMI, and metabolic health, including fasting glucose, HbA1c, and lipid panel results.
- Discuss potential interactions with current psoriasis medications, including biologics, methotrexate, cyclosporine, or other immunosuppressants.
- Review monitoring plans, such as baseline labs (CRP, IL-6 if available, metabolic panel) and regular skin assessments throughout treatment.
- Clarify realistic timelines, since some patients see skin improvement within 8–12 weeks, while others need 3–6 months.
- Request a referral to a specialist experienced in peptide therapies if you want GLP-1 treatment that addresses both skin and metabolic health comprehensively.
Risks and Side Effects from the Ozempic Label
The FDA-approved labeling for Ozempic (semaglutide) lists the most common adverse reactions, occurring in at least 5% of patients, as nausea, vomiting, diarrhea, abdominal pain, and constipation. Nausea occurred in 15.8% (0.5 mg) and 20.3% (1 mg) of semaglutide-treated patients in placebo-controlled trials versus 6.1% for placebo.
More serious but rare risks include pancreatitis and gallbladder disease. Semaglutide carries a boxed warning for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Semaglutide is a prescription medication that requires medical supervision and should not be sourced online without clinical oversight.
Why Medical Supervision Matters at Mirror Plastic Surgery
Patients with both psoriasis and metabolic concerns benefit from a coordinated, personalized plan rather than a simple prescription. Our practice, led by a Harvard-educated, Johns Hopkins-trained plastic surgeon with specialized fellowship training in aesthetic surgery and medical innovation training at Stanford, provides this integrated model of care.
The concierge approach includes 30–60 minute consultations, comprehensive lab analysis covering thyroid, liver, kidney, diabetes markers, hormone panels, and inflammatory markers, and custom peptide protocols tailored to each patient’s physiology. Our surgeon remains available 24/7 via direct text, offering ongoing support throughout treatment.
We source peptides from reputable providers with rigorous batch testing, which is a critical safety feature because peptides are not FDA-regulated. Semaglutide and other GLP-1 receptor agonists are offered as part of medically supervised protocols for patients with inflammatory conditions like psoriasis who also need metabolic support.
Request a personalized peptide therapy consultation at Mirror Plastic Surgery, tailored to your labs and health history.
Frequently Asked Questions
Is Semaglutide FDA-Approved for Psoriasis?
No. Semaglutide (Ozempic, Wegovy) is FDA-approved for type 2 diabetes, cardiovascular risk reduction, and chronic weight management. Its use for psoriasis remains off-label. The National Psoriasis Foundation Medical Board recommends GLP-1 receptor agonists as adjunctive therapy for psoriasis patients with obesity or type 2 diabetes, rather than as a primary skin-directed treatment. Patients should review this distinction with their prescribing physician before starting therapy.
How Long Does It Take to See Psoriasis Improvement with Semaglutide?
Timelines vary across patients and studies. In a 2025 open-label randomized clinical trial of obese patients with type 2 diabetes and psoriasis, semaglutide led to significant PASI improvement by 12 weeks, with median PASI falling from 21 to 10.1 Other reports show substantial reductions at 4 months, although the timing of meaningful improvement differs between studies.
The 2025 Petković-Dabić randomized trial demonstrated significant improvement after 12 weeks of treatment. Case reports have documented near-complete clearance after 10 months of therapy.1 Patients with greater weight loss often achieve faster and more pronounced skin improvement, although semaglutide also exerts direct anti-inflammatory effects independent of weight change.1
Can I Take Semaglutide with My Biologic for Psoriasis?
Most patients can safely combine semaglutide with biologic therapy under medical supervision. A 2026 cohort study showed a marked improvement in clear or almost-clear skin rates when a GLP-1 receptor agonist was added to biologic therapy, as discussed earlier. The National Psoriasis Foundation notes no new interaction signals between GLP-1 receptor agonists and biologics, methotrexate, or cyclosporine in the available literature. Combination therapy should always be coordinated with your dermatologist and prescribing physician, with ongoing monitoring.
Does Semaglutide Cause Hair Loss?
Some patients report temporary hair thinning during semaglutide therapy. Dermatologists believe this is primarily due to telogen effluvium, a stress response to rapid weight loss, rather than a direct drug effect on hair follicles. The American Academy of Dermatology advises that patients prone to hair loss lose weight slowly on GLP-1 drugs. Hair loss usually resolves as the body adjusts to the new weight and metabolic state.
What Is the Difference Between Semaglutide and Tirzepatide for Psoriasis?
Both medications act on GLP-1 receptors and have anti-inflammatory effects. Tirzepatide (Mounjaro/Zepbound) also targets GIP receptors and generally produces greater weight loss, which may translate to somewhat larger reductions in inflammatory markers. However, psoriasis-specific clinical evidence is substantially stronger for semaglutide, which has been evaluated in a randomized trial and multiple cohort studies involving hundreds of patients.
Tirzepatide is being investigated in ongoing trials for psoriasis and psoriatic arthritis, including the TOGETHER-PsO and TOGETHER-PsA trials, although head-to-head psoriasis data comparing the two agents are not yet available.
Key Takeaways for Patients Considering Semaglutide
- Semaglutide shows genuine promise for improving psoriasis, with strong 2025–2026 data supporting meaningful PASI reductions.
- Benefit appears strongest in patients with obesity or type 2 diabetes, where weight loss and direct anti-inflammatory effects work together.
- Semaglutide remains an off-label option for psoriasis and should complement, rather than replace, standard therapies such as biologics, topicals, or phototherapy.
- The risk of new-onset psoriasis appears low, at about 1 in 1,200 patients, based on observational data discussed earlier.
- Medical supervision is essential, including baseline labs, dose titration, and ongoing monitoring for side effects and skin changes.
Patients seeking a personalized, evidence-based approach to peptide therapy that addresses both inflammatory skin disease and metabolic health can work with Mirror Plastic Surgery for concierge-level care with our board-certified plastic surgeon. Start your journey with a consultation today.
References and Disclaimers
This article is for informational purposes only and does not constitute medical advice. Results vary. Semaglutide is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Mirror Plastic Surgery does not claim that semaglutide is a cure for psoriasis. Peptides are not FDA-regulated; however, Mirror Plastic Surgery sources from reputable providers with batch testing and provides medical supervision throughout treatment.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
